Eliem Therapeutics Host Virtual Investor Event Featuring Opinion Leaders in Chronic Pain Research on February 16, 2022

The event will provide an in-depth review on the unmet needs in chronic pain treatment, the precedent data supporting the mechanism of ETX-810, and ETX-810's clinical program and its potential commercial opportunity.

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Monday, February 7, 2022

Information

Tags:

GLOBE, Disorder, Investor, Company, Therapy, Patient, Review, Neuron, University, Epilepsy, Psychiatry, Chronic pain, Nasdaq, Homeostasis, R, University of Rochester, Pharmaceutical industry, Pharmacology

Geotags:

WA, UNITED KINGDOM

Organisation:

ELIEM THERAPEUTICS, INC.

Summary

Key Points:

The event will provide an in-depth review on the unmet needs in chronic pain treatment, the precedent data supporting the mechanism of ETX-810, and ETX-810's clinical program and its potential commercial opportunity.
These disorders often occur when neurons are overly excited or inhibited, leading to an imbalance, and our focus is on restoring homeostasis.
Eliem channels its experience, energy, and passion for improving patients quality of life to fuel our efforts to develop life-changing novel therapies.
At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.

SEATTLE and CAMBRIDGE, United Kingdom, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems, today announced it will host a virtual investor event, featuring two opinion leaders in chronic pain, that will be held on Wednesday, February 16, 2022 starting at 10:30 a.m. ET.

Eliem’s virtual investor event will include presentations from Bob Azelby, president and chief executive officer and Valerie Morisset, Ph.D., executive vice president, R&D and chief scientific officer as well as presentations from opinion leaders John D. Markman, M.D., Vice Chair for Clinical Research; Director, Translational Pain Research Program, University of Rochester, and Stuart Bevan, Ph.D., Professor of Pharmacology, King’s College London. The event will provide an in-depth review on the unmet needs in chronic pain treatment, the precedent data supporting the mechanism of ETX-810, and ETX-810's clinical program and its potential commercial opportunity.

A live webcast of the event, as well as a replay, will be available under "Events and Presentations" in the Investors section of the Company's website: Events and Presentations | Eliem Therapeutics, Inc. (eliemtx.com)

About Eliem Therapeutics, Inc.
Eliem Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. These disorders often occur when neurons are overly excited or inhibited, leading to an imbalance, and our focus is on restoring homeostasis. We are developing a pipeline of clinically differentiated product candidates focused on validated mechanisms of action with broad therapeutic potential to deliver improved therapeutics for patients with these disorders. Eliem channels its experience, energy, and passion for improving patients’ quality of life to fuel our efforts to develop life-changing novel therapies. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives. https://eliemtx.com/.

Investors
Chris Brinzey
ICR Westwicke
[email protected]
339-970-2843

Media
Marites Coulter
Verge Scientific
[email protected]
415-819-2214